Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Lida A Mina,1 Shannon Lim,2 Shakeela W Bahadur,1 Abdul T Firoz3 1Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 2Pharmacy Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 3Science Department, Arizona State University, Tempe, AZ, USACorrespondence:...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mina LA, Lim S, Bahadur SW, Firoz AT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	breast cancer immunotherapy pd1 pdl1 atezolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f81b79e0b475402abd9d4701e7b12d30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f81b79e0b475402abd9d4701e7b12d30
record_format	dspace
spelling	oai:doaj.org-article:f81b79e0b475402abd9d4701e7b12d302021-12-02T05:28:13ZImmunotherapy for the Treatment of Breast Cancer: Emerging New Data1179-1314https://doaj.org/article/f81b79e0b475402abd9d4701e7b12d302020-01-01T00:00:00Zhttps://www.dovepress.com/immunotherapy-for-the-treatment-of-breast-cancer-emerging-new-data-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Lida A Mina,1 Shannon Lim,2 Shakeela W Bahadur,1 Abdul T Firoz3 1Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 2Pharmacy Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 3Science Department, Arizona State University, Tempe, AZ, USACorrespondence: Lida A MinaBanner MD Anderson Cancer Center, Suite 400, 2946 E Banner Gateway Dr, Gilbert, AZ 85234, USATel +1 480 256 3676Fax +1 480 256 4624Email Lida.mina@bannerhealth.comAbstract: Breast cancer is the most common type of cancer affecting women in the United States. Triple-negative breast cancer remains the most aggressive molecular subtype secondary to a lack of therapeutic targets. The search for a target has led us to investigate immunotherapeutic agents. Immunotherapy has recently demonstrated significant breakthroughs in various types of cancers that are refractory to traditional therapies including melanoma and Non-Small Cell Lung Cancer (NSCLC). Breast cancer however remains one of the tumors that was initially least investigated because of being considered to have a low immunogenic potential and a low mutational load. Over the past few years, antiPD1/PDL1 drugs have started to make progress in the triple-negative subtype with more promising outcomes. In this report, we review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs in this challenging disease.Keywords: breast cancer, immunotherapy, PD1, PDL1, atezolizumabMina LALim SBahadur SWFiroz ATDove Medical Pressarticlebreast cancerimmunotherapypd1pdl1atezolizumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 321-328 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer immunotherapy pd1 pdl1 atezolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer immunotherapy pd1 pdl1 atezolizumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mina LA Lim S Bahadur SW Firoz AT Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
description	Lida A Mina,1 Shannon Lim,2 Shakeela W Bahadur,1 Abdul T Firoz3 1Hematology Oncology Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 2Pharmacy Department, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 3Science Department, Arizona State University, Tempe, AZ, USACorrespondence: Lida A MinaBanner MD Anderson Cancer Center, Suite 400, 2946 E Banner Gateway Dr, Gilbert, AZ 85234, USATel +1 480 256 3676Fax +1 480 256 4624Email Lida.mina@bannerhealth.comAbstract: Breast cancer is the most common type of cancer affecting women in the United States. Triple-negative breast cancer remains the most aggressive molecular subtype secondary to a lack of therapeutic targets. The search for a target has led us to investigate immunotherapeutic agents. Immunotherapy has recently demonstrated significant breakthroughs in various types of cancers that are refractory to traditional therapies including melanoma and Non-Small Cell Lung Cancer (NSCLC). Breast cancer however remains one of the tumors that was initially least investigated because of being considered to have a low immunogenic potential and a low mutational load. Over the past few years, antiPD1/PDL1 drugs have started to make progress in the triple-negative subtype with more promising outcomes. In this report, we review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs in this challenging disease.Keywords: breast cancer, immunotherapy, PD1, PDL1, atezolizumab
format	article
author	Mina LA Lim S Bahadur SW Firoz AT
author_facet	Mina LA Lim S Bahadur SW Firoz AT
author_sort	Mina LA
title	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
title_short	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
title_full	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
title_fullStr	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
title_full_unstemmed	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
title_sort	immunotherapy for the treatment of breast cancer: emerging new data
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f81b79e0b475402abd9d4701e7b12d30
work_keys_str_mv	AT minala immunotherapyforthetreatmentofbreastcanceremergingnewdata AT lims immunotherapyforthetreatmentofbreastcanceremergingnewdata AT bahadursw immunotherapyforthetreatmentofbreastcanceremergingnewdata AT firozat immunotherapyforthetreatmentofbreastcanceremergingnewdata
_version_	1718400390029901824

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Ejemplares similares